Publicaciones en colaboración con investigadores/as de Institute Catalá Oncología (121)

2024

  1. Access to melanoma drugs in Spain: a cross-sectional survey

    Clinical and Translational Oncology

  2. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/ MINOVA Study)

    Clinical Cancer Research, Vol. 30, Núm. 1, pp. 176-186

  3. Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study

    Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 732-738

  4. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

    New England Journal of Medicine, Vol. 390, Núm. 4, pp. 301-313

  5. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266

  6. High adherence to Western dietary pattern increases breast cancer risk (an EPIC-Spain study)

    Maturitas, Vol. 179

  7. Nomenclature in palliative care and renal support: Not just at the end-of-life

    Nefrologia, Vol. 44, Núm. 4, pp. 475-485

  8. Post- versus intra-operative implant for breast cancer interstitial brachytherapy: How to choose?

    Journal of Contemporary Brachytherapy, Vol. 16, Núm. 1, pp. 72-83

  9. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

  10. Prognostic Value of Lymph Node Ratio in Patients with Uterine Carcinosarcoma

    Journal of Personalized Medicine, Vol. 14, Núm. 2

  11. Pseudomonas aeruginosa Bloodstream Infections Presenting with Septic Shock in Neutropenic Cancer Patients: Impact of Empirical Antibiotic Therapy

    Microorganisms, Vol. 12, Núm. 4

  12. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

    Haematologica, Vol. 109, Núm. 7, pp. 2219-2228

  13. Status of head and neck brachytherapy in Spain in 2022

    Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 456-460

  14. The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium

    Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 352-362

  15. Very accelerated partial breast irradiation in 1 or 2 days: Late toxicity and early oncological outcome of the GEC-ESTRO VAPBI cohort

    Radiotherapy and Oncology, Vol. 194

2023

  1. Association of Mediterranean diet with survival after breast cancer diagnosis in women from nine European countries: results from the EPIC cohort study

    BMC Medicine, Vol. 21, Núm. 1

  2. Low Rate of Infectious Enterocolitis in Allogeneic Stem Cell Transplant Recipients with Acute Diarrhea: A Prospective Study by the GETH-TC

    Acta haematologica, Vol. 146, Núm. 2, pp. 161-165

  3. Prognostic factors in patients with uterine sarcoma: The SARCUT study

    International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 897-904

  4. Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme

    European Journal of Cancer, Vol. 182, pp. 3-14

  5. SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry

    Clinical and Translational Oncology, Vol. 25, Núm. 3, pp. 768-775